Global Leader of Cancer Treatments
ATB-301 is a new anti-cancer drug in combination with TGF- β2 Targeting Antisense Oligonucleotide (ASO), which selectively inhibits TGF-β, and IL-2.
- Designed based on the correlation between TGF-β overexpression and tumor progression.
- Inhibits TGF-β2 expression by complementary binding to mRNA.
- Immuno-oncology drugs are effective, but there is
a large difference in the response rate by cancer types
- TGF-β has been found to be the main cause of
resistance to immuno-oncology drugs.
- Improving the response rate in various cancer types
by combination therapy
- Increasing treatment efficacy by using the substance
which inhibits TGF-β
Completion of in-vitro
Completion of in-vivo
P1 Clinical trial
Presentations & Publications
|An American Society of Clinical Oncology Journal
|Combination therapy of anti-sense oligonucleotide targeting TGF-beta2 (TASO) and IL-2 (Proleukin) has anti-cancer effect in solid cancer||2021|
|Blockade of transforming growth factor b2 by antisense oligonucleotide improves immunotherapeutic potential of IL-2 against melanoma in a humanized mouse model||2021.06|
|Targeting transforming growth factor‑β2 by antisense oligodeoxynucleotide accelerates T cell‑mediated tumor rejection in a humanized mouse model of triple‑negative breast cancer||2022|